Abelson tyrosine kinase inhibitors (Inhibikase Therapeutics)

N/A

Report date: 2025/01/26 18:18:09
NME

Base Information

Drug NameAbelson tyrosine kinase inhibitors (Inhibikase Therapeutics)
Drug Alias Namec-Abelson tyrosine kinase inhibitors (Inhibikase Therapeutics)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitorsSynuclein alpha inhibitors
TargetsSynuclein alphaBcr-Abl tyrosine kinase
Therapy Area/IndicationsParkinson DiseaseMultiple System Atrophy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesInhibikase Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesInhibikase Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsParkinson DiseaseMultiple System Atrophy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A